Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2013 | original article | Ausgabe 21-22/2013

Wiener klinische Wochenschrift 21-22/2013

Diagnosing celiac disease in patients with a history of lymphoma: factors that matter

Wiener klinische Wochenschrift > Ausgabe 21-22/2013
Karel Balihar, Jana Kozeluhova, Vaclav Hejda, Michal Krcma, Daniel Lysak, Jitka Gorcikova, Ondrej Hes, Martin Matejovic



The aim of this study was to identify pitfalls in establishing the diagnosis of celiac disease (CD) in patients with a history of lymphoma.


A total of 103 patients with a history of lymphoma had anti-tissue transglutaminase antibodies (atTGA) and their class A, G, and M immunoglobulin (IgA, IgG) levels determined. Patients with atTGA positivity underwent enterobiopsy and CD-associated HLA locus testing.


The mean age of patients was 55 ( ± 13.5) years. The predominant lymphoma types included B-type non-Hodgkin’s lymphoma (B-NHL, 66 %), T-type NHL (8 %), and Hodgkin’s lymphoma (26 %). Serological positivity was documented in 3.9 % of cases; one patient had the diagnosis of CD confirmed by enterobiopsy. In 11 patients (10.7 %), IgA levels were decreased to a various extent; of these patients, 10 were shown to have also their IgG levels decreased. The median time from follow-up to blood collection was 58 (32–104) months. The decrease in immunoglobulin levels correlated with a more advanced stage of the tumor (Ann Arbor III–IV) at the time of diagnosis [1.4 (0.9–2.0) g/l versus 2.4 (1.5–3.0) g/l for IgA, p = 0.0001; and 9.4 (7.2–11.5) g/l versus 11.2 (10.3–12.3) g/l for IgG, p = 0.001] and older age [65 (54–72) years versus 55 (44–61) years for IgA, p = 0.04; and 69 (59–74) years versus 53 (43–61) years for IgG, p = 0.0001]. Rituximab therapy in B-NHL patients had no effect on the subsequent incidence of decreased IgA levels.


Reduced IgA and IgG levels represent important factors contributing to the low detection rate of serological screening for CD in patients with a history of lymphoma.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 21-22/2013

Wiener klinische Wochenschrift 21-22/2013 Zur Ausgabe

mitteilungen der gesellschaft

Die Österreichische Apheresegesellschaft